Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Cureus
doi 10.7759/cureus.1751
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

Practice of Dapagliflozin Application in Patients With Type 2 Diabetes Mellitus

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
2015English

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2019English

Dapagliflozin: A New Adjunct in the Treatment of Type 2 Diabetes Mellitus

International Journal of Basic & Clinical Pharmacology
2014English

Cardiovascular Safety of Sitagliptin in Patients With Type 2 Diabetes Mellitus: A Pooled Analysis

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2013English

Sulfonylureas and Cardiovascular Complications of Type 2 Diabetes Mellitus

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Alteration of Cardiovascular Autonomic Activity in Type 2 Diabetes Mellitus

International Journal of Research in Medical Sciences
2019English

Cardiovascular Safety of Non-Insulin Pharmacotherapy for Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2017English

Epidemiological Evidence of Type 2 Diabetes Mellitus, Metabolic Syndrome, and Cardiovascular Disease in Japan

Circulation Journal
MedicineCardiovascular MedicineCardiology
2012English

Obesity and Type 2 Diabetes Mellitus

Internal Medicine: Open Access
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy